FacebookTwitterGoogle+RedditEmail

Selling One Pill to Treat Side Effects of Another Pill

by MARTHA ROSENBERG

Nearly one in four US women is on antidepressants. The drugs, like Prozac, Paxil and Zoloft, may be happy pills but they are not happy-in-the-bedroom pills. Both older and newer antidepressants cause severe sexual dysfunction like diminished libido and anorgasmia, the inability to achieve orgasm, even with adequate stimulation.

Antidepressant sexual dysfunction is so common, it is used as a sales pitch by the drug manufacturers. “Wellbutrin X works for my depression with a low risk of weight gain and sexual side effects,” say glossy magazine ads showing young men whose sexuality is intact thanks to a better antidepressant. “Can your medicine do all that?” One study found 96 percent patients on a particular antidepressant developed anorgasmia. Who likes those statistics?

Now, marketers of two new sex drugs for women are acknowledging how many women are actually on antidepressants. A Dutch company developing the female libido drugs, Lybrido and Lybridos (which are not yet FDA approved or available) believes the drugs may help the antidepressant-related sexual problems, according to an article in the New York Times magazine. Lybrido contains two possible libido enhancers for women, testosterone and sildenafil, the active ingredient in Viagra. But Lybridos contains testosterone and the antidepressant buspirone, a drug already on the market and known to reverse the negative sexual side effects of antidepressants in some cases by modifying changed levels of the neurotransmitter serotonin that cause the sexual dysfunction.

Buspirone is similar to a “female Viagra” drug that almost reached the market a few years ago. Flibanserin, made by the German company Boehringer Ingelheim, was intended to treat “hypoactive sexual desire disorder” in women but rejected by the FDA. Flibanserin was similar to the antidepressant Serzone which is linked to hyper sexual arousal and the abnormal and painful erectile state known as priapism. Serzone has been withdrawn from markets.

Like Viagra (which had been intended to be an angina drug until its erectile effects appeared) flibanserin, the drug rejected three years ago, was groomed to be an antidepressant drug until its effect on female sexual desire surfaced. Some trial participants did not want to surrender their unused pills at the end of the study. But, despite medical and media excitement about flibanserin and pleas from Big Pharma, Wall Street, husbands, boyfriends and women, the FDA rejected flibanserin in 2010–not for its side effects like dizziness, nausea and sleepiness but because it didn’t seem to work.

Thanks to Big Pharma marketing, Americans increasingly seek a quick fix for “depression,” “sexual dysfunction” and other lifestyle problems. Before direct to consumer marketing of antidepressants, people did not expect to be deliriously happy for no reason or term their problems with marriages and relationships, jobs, health and money, “depression.” Medicalizing lifestyle problems is a cash cow for Big Pharma because advertising works.

Of course, there is no assurance that Lybrido and Lybridos will be approved by the FDA or gain acceptance among doctors and women. But if they do, Big Pharma’s audacious business model of selling one expensive pill to treat side effects of another expensive pill will surely please Wall Street.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Weekend Edition
May 06, 2016
Friday - Sunday
Dave Wagner
When Liberals Run Out of Patience: the Impolite Exile of Seymour Hersh
John Stauber
Strange Bedfellows: the Bizarre Coalition of Kochs, Neocons and Democrats Allied Against Trump and His #FUvoters
Rob Urie
Hillary Clinton and the End of the Democratic Party
Joshua Frank
Afghanistan: Bombing the Land of the Snow Leopard
Bill Martin
Fear of Trump: Annals of Parliamentary Cretinism
Doug Johnson Hatlem
NYC Board of Elections Suspends 2nd Official, Delays Hillary Clinton v. Bernie Sanders Results Certification
Carol Miller
Pretending the Democratic Party Platform Matters
Paul Street
Hey, Bernie, Leave Them Kids Alone
Tamara Pearson
Mexico Already Has a Giant Wall, and a Mining Company Helped to Build It
Paul Craig Roberts
Somnolent Europe, Russia, and China
Dave Lindorff
Bringing the Sanders ‘Revolution’ to Philly’s Streets
Margaret Kimberley
Obama’s Last Gasp Imperialism
Carmelo Ruiz
The New Wave of Repression in Puerto Rico
Jack Denton
Prison Labor Strike in Alabama: “We Will No Longer Contribute to Our Own Oppression”
Jeffrey St. Clair
David Bowie’s 100 Favorite Books, the CounterPunch Connection
David Rosen
Poverty in America: the Deepening Crisis
Pepe Escobar
NATO on Trade, in Europe and Asia, is Doomed
Pete Dolack
Another Goodbye to Democracy if Transatlantic Partnership is Passed
Carla Blank
Prince: Pain and Dance
Gabriel Rockhill
Media Blackout on Nuit Debout
Barry Lando
Welcome to the Machine World: the Perfect Technological Storm
Frank Stricker
Ready for the Coming Assault on Social Security? Five Things Paul Ryan and Friends Don’t Want You to Think About
Hilary Goodfriend
The Wall Street Journal is Playing Dirty in El Salvador, Again
Robert Gordon
Beyond the Wall: an In-Depth Look at U.S. Immigration Policy
Roger Annis
City at the Heart of the Alberta Tar Sands Burning to the Ground
Simon Jones
RISE: New Politics for a Tired Scotland
Rob Hager
After Indiana: Sanders Wins another Purple State, But Remains Lost in a Haze of Bad Strategy and Rigged Delegate Math
Howard Lisnoff
Father Daniel Berrigan, Anti-war Hero With a Huge Blindspot
Adam Bartley
Australia-China Relations and the Politics of Canberra’s Submarine Deal
Nyla Ali Khan
The Complexity of the Kashmir Issue: “Conflict Can and Should be Handled Constructively
Josh Hoxie
American Tax Havens: Elites Don’t Have to go to Panama to Hide Their Money–They’ve Got Delaware
Ramzy Baroud
The Spirit of Nelson Mandela in Palestine: Is His Real Legacy Being Upheld?
Alli McCracken - Raed Jarrar
#IsraelSaudi: A Match Made in Hell
George Wuerthner
Working Wilderness and Other Code Words
Robert Koehler
Cowardice and Exoneration in Kunduz
Ron Jacobs
Psychedelic Rangers Extraordinaire
Missy Comley Beattie
It’s a Shit Show!
David Macaray
Our Best Weapon Is Being Systematically Eliminated
Colin Todhunter
Future Options: From Militarism and Monsanto to Gandhi and Bhaskar Save
Binoy Kampmark
The Trump Train Chugs Along
Cesar Chelala
A Lesson of Auschwitz
John Laforge
Dan Berrigan, 1921 – 2016: “We Haven’t Lost, Because We Haven’t Given Up.”
Norman Trabulsy Jr
John Denver and My 40th High School Reunion
Charles R. Larson
Being Gay in China, Circa 1987
David Yearsley
Skepticism, Irony, and Doubt: Williams on Bach
FacebookTwitterGoogle+RedditEmail